Business Context and Reporting Period
This Form 8-K is a current report filed by Aprea Therapeutics, Inc. on February 18, 2026. The company is a Delaware corporation with its principal executive offices in Doylestown, PA, and its common stock trades on The Nasdaq Stock Market under the symbol APRE. The filing reports a specific corporate event under Item 8.01 (Other Events) regarding clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development update and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the observation of a second unconfirmed partial response (uPR) in a patient enrolled in the company's ongoing Phase 1 ACESOT-1051 dose-escalation study. This study evaluates the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. This represents a positive clinical data point compared to prior reporting periods which had not yet recorded this specific second response.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) to announce the clinical milestone. The report does not contain updated financial guidance, forward-looking projections, or specific risk factors beyond the inherent uncertainties of clinical trials implied by the "unconfirmed" nature of the response.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the full details of the press release filed as Exhibit 99.1 for specific patient data and study parameters.
- Confirm the definition and criteria for "unconfirmed partial response" within the context of the ACESOT-1051 study protocol.
- Monitor subsequent filings for confirmation of the partial response and any updates to the dose-escalation study timeline.
- Review the company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not provide financial metrics.